

Fernanda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10065134/publications.pdf>

Version: 2024-02-01

36
papers

825
citations

516710

16
h-index

526287

27
g-index

38
all docs

38
docs citations

38
times ranked

1132
citing authors

#	ARTICLE	IF	CITATIONS
1	Whole genome analysis of a schistosomiasis-transmitting freshwater snail. <i>Nature Communications</i> , 2017, 8, 15451.	12.8	216
2	Serological Screening of the <i>Schistosoma mansoni</i> Adult Worm Proteome. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2745.	3.0	48
3	Poloxamer 407 (Pluronic® F127)-based polymeric micelles for amphotericin B: In vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasis. <i>Experimental Parasitology</i> , 2016, 169, 34-42.	1.2	41
4	Antileishmanial Activity, Cytotoxicity and Mechanism of Action of Clioquinol Against <i>Leishmania infantum</i> and <i>Leishmania amazonensis</i> Species. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 236-246.	2.5	35
5	A vaccine combining two <i>Leishmania braziliensis</i> proteins offers heterologous protection against <i>Leishmania infantum</i> infection. <i>Molecular Immunology</i> , 2016, 76, 70-79.	2.2	29
6	Vaccination with a CD4+ and CD8+ T-cell epitopes-based recombinant chimeric protein derived from <i>Leishmania infantum</i> proteins confers protective immunity against visceral leishmaniasis. <i>Translational Research</i> , 2018, 200, 18-34.	5.0	29
7	<i>Schistosoma mansoni</i> : Expression of Fes-like tyrosine kinase SmFes in the tegument and terebratorium suggests its involvement in host penetration. <i>Experimental Parasitology</i> , 2007, 116, 225-232.	1.2	28
8	In vivo antileishmanial efficacy of a naphthoquinone derivate incorporated into a Pluronic® F127-based polymeric micelle system against <i>Leishmania amazonensis</i> infection. <i>Biomedicine and Pharmacotherapy</i> , 2019, 109, 779-787.	5.6	27
9	Antileishmanial activity of a naphthoquinone derivate against promastigote and amastigote stages of <i>Leishmania infantum</i> and <i>Leishmania amazonensis</i> and its mechanism of action against <i>L. amazonensis</i> species. <i>Parasitology Research</i> , 2018, 117, 391-403.	1.6	26
10	A Pluronic® F127-based polymeric micelle system containing an antileishmanial molecule is immunotherapeutic and effective in the treatment against <i>Leishmania amazonensis</i> infection. <i>Parasitology International</i> , 2019, 68, 63-72.	1.3	26
11	A next-generation proteome array for <i>Schistosoma mansoni</i> . <i>International Journal for Parasitology</i> , 2016, 46, 411-415.	3.1	22
12	A clioquinol-containing Pluronic® F127 polymeric micelle system is effective in the treatment of visceral leishmaniasis in a murine model. <i>Parasite</i> , 2020, 27, 29.	2.0	22
13	Use of Humanised Rat Basophilic Leukaemia Cell Line RS-ATL8 for the Assessment of Allergenicity of <i>Schistosoma mansoni</i> Proteins. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3124.	3.0	21
14	Immunogenicity and protective efficacy of a new <i>Leishmania</i> hypothetical protein applied as a DNA vaccine or in a recombinant form against <i>Leishmania infantum</i> infection. <i>Molecular Immunology</i> , 2019, 106, 108-118.	2.2	20
15	A vaccine composed of a hypothetical protein and the eukaryotic initiation factor 5a from <i>Leishmania braziliensis</i> cross-protection against <i>Leishmania amazonensis</i> infection. <i>Immunobiology</i> , 2017, 222, 251-260.	1.9	18
16	A <i>Leishmania</i> hypothetical protein-containing liposome-based formulation is highly immunogenic and induces protection against visceral leishmaniasis. <i>Cytokine</i> , 2018, 111, 131-139.	3.2	18
17	Screening diagnostic candidates from <i>Leishmania infantum</i> proteins for human visceral leishmaniasis using an immunoproteomics approach. <i>Parasitology</i> , 2019, 146, 1467-1476.	1.5	17
18	In silico <i>Leishmania</i> proteome mining applied to identify drug target potential to be used to treat against visceral and tegumentary leishmaniasis. <i>Journal of Molecular Graphics and Modelling</i> , 2019, 87, 89-97.	2.4	16

#	ARTICLE	IF	CITATIONS
19	A chloroquinoline derivate presents effective in vitro and in vivo antileishmanial activity against Leishmania species that cause tegumentary and visceral leishmaniasis. Parasitology International, 2019, 73, 101966.	1.3	15
20	Detecting anti-“SARS-CoV-2 antibodies in urine samples: A noninvasive and sensitive way to assay COVID-19 immune conversion. Science Advances, 2022, 8, eabn7424.	10.3	14
21	Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis. Experimental Parasitology, 2019, 199, 30-37.	1.2	13
22	Molecular analysis of SmFes, a tyrosine kinase of Schistosoma mansoni orthologous to the members of the Fes/Fps/Fer family. Biochemical and Biophysical Research Communications, 2007, 360, 163-172.	2.1	11
23	Immunodiagnosis of human and canine visceral leishmaniasis using recombinant Leishmania infantum Prohibitin protein and a synthetic peptide containing its conformational B-cell epitope. Journal of Immunological Methods, 2019, 474, 112641.	1.4	11
24	Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis. Parasitology Research, 2021, 120, 321-335.	1.6	11
25	Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis. Experimental Parasitology, 2021, 221, 108059.	1.2	11
26	A Leishmania infantum hypothetical protein evaluated as a recombinant protein and specific B-cell epitope for the serodiagnosis and prognosis of visceral leishmaniasis. Acta Tropica, 2020, 203, 105318.	2.0	9
27	Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis. Medical Microbiology and Immunology, 2021, 210, 133-147.	4.8	9
28	Evaluation of Leishmania infantum pyridoxal kinase protein for the diagnosis of human and canine visceral leishmaniasis. Immunology Letters, 2020, 220, 11-20.	2.5	8
29	Leishmania infantum pyridoxal kinase evaluated in a recombinant protein and DNA vaccine to protects against visceral leishmaniasis. Molecular Immunology, 2020, 124, 161-171.	2.2	7
30	An immunoproteomics approach to identify Leishmania infantum proteins to be applied for the diagnosis of visceral leishmaniasis and human immunodeficiency virus co-infection. Parasitology, 2020, 147, 932-939.	1.5	7
31	Biotechnological applications from a Leishmania amastigote-specific hypothetical protein in the canine and human visceral leishmaniasis. Microbial Pathogenesis, 2020, 147, 104283.	2.9	6
32	In vitro and in vivo antileishmanial activity of Î²-acetyl-digitoxin, a cardenolide of Digitalis lanata potentially useful to treat visceral leishmaniasis. Parasite, 2021, 28, 38.	2.0	6
33	A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis. Cellular Immunology, 2020, 356, 104194.	3.0	5
34	A new Leishmania hypothetical protein can be used for accurate serodiagnosis of canine and human visceral leishmaniasis and as a potential prognostic marker for human disease. Experimental Parasitology, 2020, 216, 107941.	1.2	5
35	Leishmania eukaryotic elongation Factor-1 beta protein is immunogenic and induces parasitological protection in mice against Leishmania infantum infection. Microbial Pathogenesis, 2021, 151, 104745.	2.9	3
36	Sensitive and specific serodiagnosis of tegumentary leishmaniasis using a new chimeric protein based on specific B-cell epitopes of Leishmania antigenic proteins. Microbial Pathogenesis, 2022, 162, 105341.	2.9	3